- Home
- PRFX vs ONCO Comparison
PRFX vs ONCO Comparison
Compare PRFX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRFX | ONCO |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRFX | ONCO |
|---|---|---|
| Price | $2.29 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.2K | ★ 358.7K |
| Earning Date | 04-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.05 |
| 52 Week High | $3.71 | $7.65 |
Technical Indicators
Market Signals| Indicator | PRFX | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 33.03 |
| Support Level | $1.28 | $0.45 |
| Resistance Level | $3.65 | $0.95 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 11.08 | 3.33 |
Price Performance
Historical ComparisonAbout PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.